Results of ABO-Incompatible Liver Transplantation Using a Simplified Protocol at a Single Institution

• DOI: 10.1016/j.transproceed.2015.02.004
• Publication Date: 2015-04-17T03:15:43Z
• Authors: J. Lee; J.G. Lee; J.J. Lee; M.S. Kim; M.K. Ju; G.H. Choi; J.S. Choi; S.I. Kim; D.J. Joo
• Keywords: Adult; Graft Rejection; Male; Infusions; Adolescent; ABO Blood-Group System/immunology*; Immunoglobulins; 610; Liver Transplantation/methods*; Blood Group Incompatibility/immunology; End Stage Liver Disease/immunology; ABO Blood-Group System; End Stage Liver Disease; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Rituximab/therapeutic use; 617; Living Donors; Humans; End Stage Liver Disease/surgery*; Preschool; Child; Infusions, Intravenous; Plasma Exchange; Infant, Newborn; Immunoglobulins, Intravenous; Infant; Blood Group Incompatibility/therapy*; Graft Rejection/immunology; Middle Aged; Newborn; Combined Modality Therapy; Liver Transplantation; 3. Good health; Treatment Outcome; Blood Group Incompatibility; Child, Preschool; Splenectomy; Immunosuppressive Agents/therapeutic use; Female; Graft Rejection/prevention & control*; Intravenous/therapeutic use; Intravenous; Transplantation Conditioning/methods*; Immunosuppressive Agents

Because of the development of various desensitization strategies, ABO-incompatible (ABOi) living donor liver transplantation (LDLT) has become a feasible option for patients with end-stage liver disease. However, there has been no united desensitization protocol for ABOi LDLT. We analyzed the outcomes after establishment of simplified protocol without splenectomy, intravenous immunoglobulin, and local infusion therapy.We analyzed 19 ABOi LDLT cases that had been performed between January 2012 and December 2013, without splenectomy and local infusion. We used a single dose of rituximab (375 mg/m(2)) 10 days before transplantation and several series of plasma exchange according to the recipients' iso-agglutinin titer-to-target titer ratio of 1:32.Nineteen recipients received ABOi LTs from living donors. The mean initial immunoglobulin (Ig) M and IgG anti-ABO titers were 76.63 ± 78.81 (range, 8∼256) and 162.53 ± 464.1 (0∼2048). We performed preoperative plasma exchange to 16 recipients (mean number of sessions, 3.58; range, 1-10). After surgery, 9 patients received plasma exchange (mean, 1.84; range 1∼14). One death occurred as the result of pneumonia (5.3%). There were 4 cases of acute rejections (21.1%), and all of them were treated successfully with steroid pulse or thymoglobulin. Antibody-mediated rejection and graft failure did not occur. Six cases of postoperative complications (31.6%) occurred, including 3 cases of infections. There were 2 cases of biliary anastomotic stricture (10.5%) and 1 case of portal vein stenosis (5.3%).ABOi LDLT with the use of simplified protocol can be safely performed without increased risk of antibody-mediated rejection and other complications.